{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:49:25Z","timestamp":1790887765338,"version":"4.1.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>Imatinib mesylate (Glivec; Novartis AG, Basel, Switzerland) is a tyrosine kinase inhibitor which is used in the treatment of oncologic diseases like chronic myeloid leukemia and gastrointestinal stroma tumor (GIST). Among cutaneous side effects, bullous reactions are rare. The authors describe the case of a 66-year-old woman developing blistering and skin fragility on her hands, foot, lower legs, and back after intake of imatinib for treatment of GIST. Biopsy showed vacuolar alteration at the dermoepidermal junction (DEJ) associated with a few lymphocytes and a subepidermal blister. The upper papillary dermis below the vacuolar alteration and below the blister showed hyalinization and loss of elastic microfibrils. Direct immunofluorescence was negative for deposits of immunoglobulins. Immunofluorescence on cryosections revealed loss of laminin and collagen IV in vacuoles at the DEJ. Electron microscopy showed dissolution of lamina lucida and lamina densa of the basement membrane below as well as next to the vacuoles and blister. In conclusion, the authors present the first patient with GIST with blistering and skin fragility due to imatinib therapy. As a pathophysiological explanation the authors propose loss of laminin and collagen IV at the DEJ leading to basement membrane instability and blistering. This case also suggests additional features reminiscent of lichen sclerosus induced by imatinib, a drug which is actually known for its antifibrotic effects.<\/jats:p>","DOI":"10.1097\/dad.0000000000001063","type":"journal-article","created":{"date-parts":[[2017,11,28]],"date-time":"2017-11-28T21:09:52Z","timestamp":1511903392000},"page":"371-374","source":"Crossref","is-referenced-by-count":9,"title":["Blistering and Skin Fragility Due to Imatinib Therapy: Loss of Laminin and Collagen IV as a Possible Cause of Cutaneous Basement Membrane Instability"],"prefix":"10.1097","volume":"40","author":[{"given":"Sebastian","family":"M\u00fchl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Ehrchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Metze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230908","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ad.2013.01.009","article-title":"Adverse skin effects of imatinib, a tyrosine kinase inhibitor","volume":"105","author":"Pretel-Irazabal","year":"2014","journal-title":"Actas Dermosifiliogr."},{"key":"R2-20230908","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med."},{"key":"R3-20230908","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/jdv.12172","article-title":"Imatinib, dasatinib and nilotinib: a review of adversecutaneous reactions with emphasis on our clinical experience","volume":"27","author":"Brazzelli","year":"2013","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"R4-20230908","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1177\/1078155213518226","article-title":"Late onset imatinib-induced Stevens-Johnson syndrome","volume":"20","author":"Bois","year":"2014","journal-title":"J Oncol Pharm Pract."},{"key":"R5-20230908","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1056\/NEJM200108233450814","article-title":"Cutaneous reactions to STI571","volume":"345","author":"Brouard","year":"2001","journal-title":"N Engl J Med."},{"key":"R6-20230908","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1468-3083.2009.03456.x","article-title":"Skin fragility and blistering with imatinib mesylate","volume":"24","author":"Verma","year":"2010","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"R7-20230908","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/j.1365-2230.2011.04289.x","article-title":"Skin fragility and blistering secondary to imatinib","volume":"37","author":"Reddy","year":"2012","journal-title":"Clin Exp Dermatol."},{"key":"R8-20230908","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1111\/j.1365-2133.2006.07276.x","article-title":"Imatinib-associated lichenoid eruption: acitretin treatment allows maintained antineoplastic effect","volume":"154","author":"Dalmau","year":"2006","journal-title":"Br J Dermatol."},{"key":"R9-20230908","doi-asserted-by":"crossref","first-page":"351","DOI":"10.4103\/0019-5154.82502","article-title":"Imatinib induced lichen planus","volume":"56","author":"Sudha","year":"2011","journal-title":"Indian J Dermatol."},{"key":"R10-20230908","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1093\/annonc\/mdn389","article-title":"Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib","volume":"19","author":"Lacouture","year":"2008","journal-title":"Ann Oncol."},{"key":"R11-20230908","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00000478-199804000-00013","article-title":"Light microscopic criteria for the diagnosis of early vulvar lichen sclerosus: a comparison with lichen planus","volume":"22","author":"Fung","year":"1998","journal-title":"Am J Surg Pathol."},{"key":"R12-20230908","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1046\/j.1365-2133.1997.6061582.x","article-title":"The basement membrane zone in lichen sclerosus: an immunohistochemical study","volume":"136","author":"Marren","year":"1997","journal-title":"Br J Dermatol."},{"key":"R13-20230908","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/00000372-200404000-00002","article-title":"Alterations of basement membrane zone in bullous and non-bullous variants of extragenital lichen sclerosus","volume":"26","author":"Kowalewski","year":"2004","journal-title":"Am J Dermatopathol."},{"key":"R14-20230908","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1001\/archderm.1985.01660090097022","article-title":"Epidermolysis bullosa acquisita with negative direct immunofluorescence","volume":"121","author":"Lacour","year":"1985","journal-title":"Arch Dermatol."},{"key":"R15-20230908","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.matbio.2013.07.007","article-title":"Disorders of the cutaneous basement membrane zone\u2013the paradigm of epidermolysis bullosa","volume":"33","author":"Bruckner-Tuderman","year":"2014","journal-title":"Matrix Biol."},{"key":"R16-20230908","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00418-009-0586-0","article-title":"Basement membranes in skin: unique matrix structures with diverse functions?","volume":"132","author":"Breitkreutz","year":"2009","journal-title":"Histochem Cell Biol."},{"key":"R17-20230908","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11926-010-0142-x","article-title":"Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials","volume":"13","author":"Iwamoto","year":"2011","journal-title":"Curr Rheumatol Rep."},{"key":"R18-20230908","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/j.1600-0560.2009.01398.x","article-title":"Development of lichen sclerosus et atrophicus while receiving a therapeutic dose of imatinib mesylate for chronic myelogenous leukemia","volume":"37","author":"Skupsky","year":"2010","journal-title":"J Cutan Pathol."},{"key":"R19-20230908","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/bs.ctm.2015.05.003","article-title":"Epidermal basement membrane in health and disease","volume":"76","author":"Has","year":"2015","journal-title":"Curr Top Membr."},{"key":"R20-20230908","doi-asserted-by":"crossref","first-page":"179784","DOI":"10.1155\/2013\/179784","article-title":"Skin basement membrane: the foundation of epidermal integrity\u2014BM functions and diverse roles of bridging molecules nidogen and perlecan","volume":"2013","author":"Breitkreutz","year":"2013","journal-title":"Biomed Res Int."},{"key":"R21-20230908","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000111507","article-title":"The effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts: a preclinical study","volume":"216","author":"Soria","year":"2008","journal-title":"Dermatology."}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000372-201805000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T04:12:26Z","timestamp":1694146346000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000372-201805000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000001063","relation":{},"ISSN":["0193-1091"],"issn-type":[{"value":"0193-1091","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]}}}